OnKure Therapeutics (OKUR) Common Equity (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Common Equity came in at $184.4 million in Q1 2026, up 103.37% YoY from $90.6 million in Q1 2025, and up 228.12% on a QoQ basis from $56.2 million in Q4 2025.
OnKure Therapeutics (OKUR) Common Equity (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Common Equity data on file, last reported at $184.4 million in Q1 2026.
- Quarterly Common Equity rose 103.37% year-over-year to $184.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.4 million (up 103.37% YoY) and the FY2025 annual result came in at $56.2 million, down 45.89% from the prior year.
- Common Equity advanced to $184.4 million in Q1 2026, from $56.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $184.4 million in Q1 2026 to a low of -$135.0 million in Q3 2024.
- A 5-year average of $44.7 million and a median of $87.1 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 377.76% — and 2024, when it sank 227.76%.
- Tracing OKUR's Common Equity over 5 years: stood at -$54.4 million in 2022, then plunged by 87.15% to -$101.8 million in 2023, then soared by 201.95% to $103.8 million in 2024, then slumped by 45.89% to $56.2 million in 2025, then soared by 228.12% to $184.4 million in 2026.
- The last three Common Equity figures came in at $184.4 million (Q1 2026), $56.2 million (Q4 2025), and $66.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 172.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 172.11 Mn |
| Mar 31, 2026 | 184.35 Mn |
| Dec 31, 2025 | 56.18 Mn |
| Sep 30, 2025 | 66.43 Mn |
| Jun 30, 2025 | 78.17 Mn |
| Mar 31, 2025 | 90.65 Mn |
| Dec 31, 2024 | 103.83 Mn |
| Sep 30, 2024 | -135.05 Mn |
| Jun 30, 2024 | -123.58 Mn |
| Mar 31, 2024 | -111.26 Mn |
| Dec 31, 2023 | -101.84 Mn |
| Sep 30, 2023 | 114.94 Mn |
| Jun 30, 2023 | 132.53 Mn |
| Mar 31, 2023 | 87.08 Mn |
| Dec 31, 2022 | -54.42 Mn |
| Sep 30, 2022 | 112.05 Mn |
| Jun 30, 2022 | 124.16 Mn |
| Mar 31, 2022 | 135.32 Mn |
| Dec 31, 2021 | 147.21 Mn |
| Sep 30, 2021 | 156.21 Mn |